The transcription factor suppressor of mothers against decapentaplegic homolog 3 (SMAD3) plays a decisive role in shaping the epigenetic profile of CAFs and its targeting with the potent and selective SMAD3 inhibitor SIS3 has demonstrated significant efficacy in preclinical lung cancer models 16. This evidence concerns the gene SMAD3 and lung carcinoma.